Posted: Wed Nov 19, 2008 10:46 pm Post subject: Start Of Phase III Trial On The Anti-influenza Drug CS-8958
CS-8958, a long-acting neuraminidase inhibitor (LANI), was discovered by Daiichi Sankyo and is co-owned with Biota Holdings Limited.
CS-8958 is an inhaled formulation for influenza treatment and it is expected that single administration of CS-8958 will be efficacious for the treatment of influenza.
CS-8958 shows efficacy against H5N1 avian influenza virus as well as influenza A and B viruses in preclinical tests.
In this double-blind non-inferiority study, it is expected to confirm that single inhalation of CS-8958 is equally effective to 75 mg of oseltamivir administered orally twice daily for 5 consecutive days. Also, the safety of CS-8958 will be assessed in this study.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum